USP48 and acute myeloid leukemia: PR-619, a broad DUB inhibitor that includes USP48, is considered a promising anti-cancer drug.17 Studies have shown that PR-619 induces apoptosis and autophagy through ubi-protein aggregation-activated ER stress in esophageal squamous cell carcinoma.18 It can also enhance the cytotoxic and apoptotic effects of cisplatin by suppressing c-Myc in cisplatin-resistant urothelial carcinoma cells.19 Recently, PR-619 was found to induce ferroptosis and trigger antitumor immunity in colon cancer cells.20 However, little is known about effects and mechanism of PR-619 in AML.